Mar 31, 2020
Jazz Pharmaceuticals Provides COVID-19 Business Update
Mar 25, 2020
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Sep 25, 2019
Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019
Sep 16, 2019
Harmony Biosciences To Present Clinical Data On WAKIX® (pitolisant) At Upcoming World Sleep 2019
Aug 12, 2019
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
Jul 16, 2019
Narcolepsy Drugs Market to Garner $5.36 Bn, Globally, by 2026 at 10.3% CAGR: Says Allied Market Research
Jun 04, 2019
Harmony Biosciences To Present New Data On Pitolisant In Patients With Narcolepsy At SLEEP 2019 Meeting
May 09, 2019
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Mar 26, 2019
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Mar 20, 2019
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Dec 21, 2018
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Nov 29, 2018
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
Oct 29, 2018
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Oct 23, 2018
Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018
Sep 11, 2018
Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch
Aug 29, 2018
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Jul 24, 2018
Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018
Jun 27, 2018
Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients